Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
November 13, 2021 at 14:15 PM EST
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.
